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 Under pressure overload, mitochondrial
deoxyribonucleic acid containing the
unmethylated cytidine-phosphate-
guanosine motif is accumulated in car-
diomyocytes and stimulates Toll-like
receptor 9, resulting in inflammation and
heart failure.
 Treatment with E6446, (6-[3-(pyrrolidin-
1-yl)propoxy)-2-(4-(3-(pyrrolidin-1-yl)
propoxy)phenyl]benzo[d]oxazole), a
specific Toll-like receptor 9 inhibitor,
prevented the development and slowed
the progression of left ventricular dilata-
tion and cardiac dysfunction in mice after
pressure overload.
 E6446 attenuated the inflammatory
responses in the pressure-overloaded
mouse heart, even though the accumula-
tion of mitochondrial deoxyribonucleic
acid in cardiomyocytes was observed.
 E6446 could be a new therapeutic agent
against heart failure.https://doi.org/10.1016/j.jacbts.2019.01.002
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349SUMMARY
AB BAND ACRONYM S
CCCP = carbonyl cyanide m-
chlorophenyl hydrazine
CpG = cytidine-phosphate-
guanosine
CpG ODN = unmethylated
cytidine-phosphate-guanosine
containing
oligodeoxynucleotide
DNA = deoxyribonucleic acid
E6446 = (6-[3-(pyrrolidin-1-
yl)propoxy)-2-(4-(3-
(pyrrolidin-1-yl)propoxy)
yl]benzo[d]oxazole)Mitochondrial deoxyribonucleic acid, containing the unmethylated cytidine-phosphate-guanosine motif, stim-
ulates Toll-like receptor 9 to induce inflammation and heart failure. A small chemical, E6446 [(6-[3-(pyrrolidin-
1-yl)propoxy)-2-(4-(3-(pyrrolidin-1-yl)propoxy)phenyl]benzo[d]oxazole)], is a specific Toll-like receptor 9
inhibitor in cardiomyocytes. In this study, we showed that E6446 exerts beneficial effects for the prevention
and treatment of pressure overload–induced heart failure in mice. When administered before the operation
and chronically thereafter, E6446 prevented the development of left ventricular dilatation as well as cardiac
dysfunction, fibrosis, and inflammation. Furthermore, when administered after the manifestation of cardiac
dysfunction, E6446 slowed progression of cardiac remodeling. Thus, the inhibitor may be a novel therapeutic
agent for treating patients with heart failure. (J Am Coll Cardiol Basic Trans Science 2019;4:348–63)
© 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).= 5-ethynyl-20-phen
EdUdeoxyuridine
IL = interleukin
IVSd = end-diastolic
interventricular septal wall
thickness
LAMP = lysosome-associated
membrane protein
LC = microtubule-associated
protein light chain
LPS = lipopolysaccharide
LV = left ventricular
mRNA = messenger
ribonucleic acid
TAC = transverse aortic
constriction
TLR = Toll-like receptor
TNF = tumor necrosis factorH eart failure is a complex disease associatedwith high levels of morbidity and mortalityand marked reductions in quality of life.
Previous extensive studies on heart failure have re-
ported an important role for proinflammatory cyto-
kines in its pathogenesis (1). Circulating levels of
proinflammatory cytokines, including tumor necrosis
factor (TNF)-a, are related to the severity and prog-
nosis of the disease. However, the targeted anti-
TNF-a approaches were neutral with respect to the
primary endpoints of the trial or resulted in wors-
ening heart failure or death (2,3). In addition to
TNF-a, the pro-inflammatory cytokines that are elab-
orated in heart failure include other members of the
TNF superfamily, members of the interleukin-1 fam-
ily, and interleukin (IL)-6 (1). Recognizing the molec-
ular mechanism underlying the developing
inflammation in heart failure is essential for devel-
oping strategies to control disease progression,
including therapeutic drugs.
Mitochondrial deoxyribonucleic acid (DNA)
contains the unmethylated cytidine-phosphate-
guanosine (CpG) motif, which stimulates Toll-like
receptor (TLR) 9 to induce inflammation (4,5). Mito-
chondria damaged by external hemodynamic stress
are degraded by the autophagy/lysosome system in
cardiomyocytes (6). Insufficient degradation of
mitochondrial DNA mediated through autophagy in
pressure-overloaded mouse hearts leads to its bind-
ing to TLR9 to induce inflammation and heart failure
(7). In failing mouse hearts, mitochondrial DNA is
located in autolysosomes. Furthermore, TLR9 abla-
tion in pressure-overloaded mice attenuated the
development of inflammation and heart failure.
Thus, interference with TLR9 function by small
molecules is likely to produce a better clinical
outcome by preventing its aberrant inflammatory
responses.E6446 (6-[3-(pyrrolidin-1-yl)propoxy)-2-
(4-(3-(pyrrolidin-1-yl)propoxy)phenyl]benzo
[d]oxazole), is a synthetic antagonist of
nucleic acid–sensing TLRs and is orally
bioactive (8,9). In vitro, E6446 specifically
inhibits the activation of TLR9 (8). Others
have reported that the compound inhibits
TLR9 but also TLR7 in a ligand-dependent
manner (9). When E6446 is administered to
mice, it suppresses inflammatory responses
to challenge doses of unmethylated CpG
containing oligodeoxynucleotide (CpG ODN)
(8,9). When E6446 is administered chroni-
cally in mouse cerebral malaria and sponta-
neous lupus models, the compound inhibits
cytokine production with prevention of signs
of cerebral malaria and circulating antinuclear anti-
bodies, respectively.
In the present study, the efficacy of oral treatment
with E6446 was evaluated on mouse pressure
overload–induced heart failure models. Our results
indicate that E6446 exerts beneficial effects for the
prevention and treatment of heart failure in mice and
might be a novel therapeutic agent for treating pa-
tients with heart failure.
METHODS
CELL CULTURE. Adult cardiomyocytes were isolated
from 10- to 12-week-old C57BL/6J male mice (CLEA
Japan, Inc., Tokyo, Japan) by using a Langendorff
system and were then cultured (7).
RIBONUCLEIC ACID ANALYSIS. Total ribonucleic
acid (RNA) was extracted from the left ventricle or
cultured cardiomyocytes by using the TRIzol reagent
(Thermo Fisher Scientific, Waltham, Massachusetts)
and reverse transcribed by using TaqMan Reverse
Transcription Reagents (Thermo Fisher Scientific) (7).
TABLE 1 Echocardiographic Parameters of All Mice Subjected to
TAC Operation for 2 Weeks
Baseline (n ¼ 30) TAC for 2 Weeks (n ¼ 30)
LVDd, mm 2.31  0.02 2.77  0.03*
LVDs, mm 0.88  0.01 1.45  0.03*
LVFS, % 62.0  0.40 47.8  0.71*
IVSd, mm 0.92  0.00 1.04  0.01*
LVPWd, mm 0.86  0.01 1.02  0.01*
Heart rate, beats/min 696  3.4 685  4.3
LV mass, mg 58.7  0.7 96.6  2.1*
The echocardiographic parameters of the mice were obtained 2 weeks after the
operation. Values are mean  SE. *p < 0.05 vs. baseline.
IVSd ¼ end-diastolic interventricular septal wall thickness; LV ¼ left ventricular;
LVDd ¼ end-diastolic left ventricular internal dimension; LVDs ¼ end-systolic left
ventricular internal dimension; LVFS ¼ left ventricular fractional shortening;
LVPWd ¼ end-diastolic left ventricular posterior wall thickness; TAC ¼ transverse
aortic constriction.
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performed by using the Platinum Quantitative PCR
SuperMix-UDG (Thermo Fisher Scientific). Relative
levels of gene expression were normalized to the
Gapdh messenger RNA (mRNA) expression. The
primers (Thermo Fisher Scientific: Assay identity)
used were as follows: Nppa, Mm01255747_g1; Nppb,
Mm00435304_g1; Col1a2, Mm01165107_m1; Col3a1,
Mm00802331_m1; Gapdh, 4352339E; Il6,
Mm99999064_m1; Il1b, Mm01336189_m1; and Tnfa,
Mm00443260_g1.
IMMUNOFLUORESCENCE MICROSCOPY. Adult mouse
cardiomyocytes on laminin-coated glass-based dishes
(IWAKI Cell Biology, Bio-REV Pte. Ltd., Singapore)
were incubated with 100 nmol/l carbonyl cyanide m-
chlorophenyl hydrazine (CCCP) for 6 h. To estimate
mitochondrial membrane potential, the cells were
treated with 10 nmol/l of tetramethylrhodamine ethyl
ester (Molecular Probes, Eugene, Oregon) for 30 min.
To visualize DNA and autophagosomes, the cells were
incubated in three-dimensional gel with Cellmatrix
I-A (Nitta Gelatin Inc., Osaka, Japan) and fixed with
methanol at 30C for 15 min. The cells were incu-
bated with anti–microtubule-associated protein light
chain (LC) 3B antibody (Cell Signaling Technology,
Danvers, Massachusetts) overnight at 4C, followed
by staining with anti-rabbit Alexa 568 secondary
antibody (Abcam, Cambridge, United Kingdom)
overnight. The cells were incubated with 100-fold
diluted PicoGreen (Thermo Fisher Scientific) for 30
min before confocal microscopic analysis using an
FV-1000D microscope (Olympus, Tokyo, Japan) (7).
ANIMAL STUDY. The investigation conforms to the
Position of the American Heart Association on
Research Animal Use adopted by the American Heart
Association on November 11, 1984. All in vivo andin vitro experimental protocols were conducted un-
der the supervision of the Animal Research Commit-
tee of Osaka University and in accordance with the
Guidelines for Animal Experiments of Osaka Univer-
sity and the Japanese Animal Protection and Man-
agement Law.
The 10- to 12-week-old male C57BL/6J mice were
subjected to transverse aortic constriction (TAC) sur-
gery (10). Sham-operated animals underwent the
same operation without aortic constriction. Blood
pressure was measured noninvasively on mice anes-
thetized with 2.5% tribromoethanol by using a pres-
sure monitor (Model MK-2000, Muromachi Kikai Co.,
Ltd., Tokyo, Japan). The pressure gradient across TAC
was estimated by the difference in blood pressure
between both arms by using a pressure monitor. Ul-
trasonography (Sonos 5500, equipped with a 15-MHz
linear probe, Philips Medical Systems, Cambridge,
Massachusetts) was used for assessing left ventricular
(LV) size and function on conscious mice.
DRUG AND TREATMENT. E6446 (Eisai, Inc., Andover,
Massachusetts) was dissolved in dimethyl sulfoxide
(final 0.04% v/v) for experiments. Isolated car-
diomyocytes were pretreated with E6446 (0 to 10
mmol/l) for 1 h, followed by treatment with 1 mg/ml of
lipopolysaccharide (LPS) (FUJIFILM WAKO Pure
Chemical Co., Osaka, Japan), 2 mmol/l of loxoribine
(InvivoGen, San Diego, California), or 5 mmol/l of type B
CpG ODN (ODN1668, InvivoGen) for 6 h. To examine
the effect of E6446 on the level of cytokine mRNAs,
cardiomyocytes were pretreated with 10 mmol/l of
E6446 for 1 h, followed by treatment with 100 nmol/l of
CCCP for 6 h.
For the in vivo ODN1668 challenge experiments
with E6446, the mice were orally administered E6446
at a dose of 1.5 mg/200 ml per mouse using animal
feeding needles (Natsume Seisakusho Co., Ltd.,
Tokyo, Japan). One, two, or 3 days later, the mice
were injected intraperitoneally with 60 mg/mouse of
ODN1668 2 h before sacrifice, following intraperito-
neal injection of 20 mg/mouse of D-galactosamine
(MilliporeSigma, Burlington, Massachusetts) for 30
min. In the prevention study, E6446 administration
was started 2 days before the operation. Mice were
administered E6446 orally at a dose of 1.5 mg/mouse
or its vehicle (saline) as a control every 2 days. In the
treatment study, 30 mice were subjected to TAC
operation for 2 weeks. Ten mice with fractional
shortening >50% were excluded from the study. The
remaining 20 mice were randomized to the saline-
and E6446-treated groups and then orally adminis-
tered saline or E6446 (1.5 mg/mouse) every 2 days
(Table 1).
FIGURE 1 Selectivity of E6446
The expression level of cytokine messenger ribonucleic acid in cardiomyocytes with increasing concentrations of E6446, (6-[3-(pyrrolidin-1-
yl)propoxy)-2-(4-(3-(pyrrolidin-1-yl)propoxy)phenyl]benzo[d]oxazole) (n ¼ 3). Cardiomyocytes were treated with 0 to 10 mmol/l of E6446
for 1 h, followed by (A) 5 mmol/l ODN1668, (B) 1 mg/ml of lipopolysaccharide (LPS), or (C) 2 mmol/l of loxoribine for 6 h. Control groups were
treated with vehicle. Data were normalized to the content of Gapdh messenger ribonucleic acid. Values are mean  SE. Bars in graphs
indicate p < 0.05. *p < 0.05 versus both control groups.
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IL-6, IL-1B, and TNF-a serum levels were measured
with an enzyme-linked immunoadsorbent assay kit
(Thermo Fisher Scientific for IL-6 and IL-1B, R and D
Systems [Minneapolis, Minnesota] for TNF-a).HISTOLOGICAL ANALYSIS. Heart samples were fixed
in buffered 4% paraformaldehyde solution and
embedded in paraffin (10). Fibrosis fraction was
quantified by using ImageJ software (National In-
stitutes of Health, Bethesda, Maryland) and
FIGURE 2 Effect of E6446 on Mitochondrial Damage–Induced Cytokine Messenger Ribonucleic Acid Production in Isolated Adult
Mouse Cardiomyocytes
(A) Disruption of mitochondrial membrane potential by carbonyl cyanide m-chlorophenyl hydrazine (CCCP). Isolated cardiomyocytes were
incubated with 100 nmol/l CCCP for 6 h and stained with tetramethylrhodamine ethyl ester (TMRE). Scale bar, 20 mm. The right graph shows
the proportion of TMRE-positive cells. (B) Double staining of E6446-treated cardiomyocytes stimulated with CCCP using PicoGreen (green)
and anti–microtubule-associated protein light chain (LC) 3B antibody (red). Low-magnified images are shown in the left panels. Scale bar, 20
mm. Higher magnified images of the squared areas are shown in the right panels. Scale bar, 5 mm. Arrows indicate PicoGreen and LC3B
merged deposits. The right graph shows the number of PicoGreen and LC3B double-positive deposits per cell. Ten or more cells were
analyzed for each experiment. (C) Inhibition of cytokine messenger ribonucleic acid expression in CCCP-stimulated cardiomyocytes by E6446.
Cardiomyocytes were treated with 10 mmol/l E6446 for 1 h, followed by 100 nmol/l CCCP for 6 h. Values are mean  SE (n ¼ 3). *p < 0.05
versus corresponding controls. †p < 0.05 versus all other groups. Abbreviation as in Figure 1.
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FIGURE 3 Determination of the Experimental Conditions for E6446 Administration
The time dependence of (A) cytokine protein and (B) messenger ribonucleic acid (mRNA) expression in the heart after injection with
ODN1668. Mice (body weight 24.4 to 25.8 g) were pretreated with oral administration of 1.5 mg/mouse (60 mg/kg) of E6446 1, 2, or 3 days
before intraperitoneal injection with 60 mg/mouse of ODN1668. Two hours after ODN1668 injection, mice were sacrificed for analysis (see
Figure 9A). Dose dependency in the inhibition of (C) cytokine protein and (D) mRNA expression after ODN1668 injection with increasing
concentrations of E6446. Two days after oral administration with the indicated dose of E6446, mice were administered an intraperitoneal
injection of 60 mg/mouse of ODN1668. Two hours later, mice were sacrificed for analysis (see Figure 9B). Data were normalized to the
content of Gapdh mRNA in B and D. Values are mean  SE (n ¼ 3). Bars in graphs indicate p < 0.05. IL ¼ interleukin; TNF ¼ tumor necrosis
factor; other abbreviation as in Figure 1.
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FIGURE 4 Improvement of Echocardiographic Parameters by Treatment With E6446 Initiated Before TAC
The oral administration of E6446 (1.5 mg/mouse) was performed every 2 days from 2 days before transverse aortic constriction (TAC) (see
Figure 10A). (A) Pressure gradient across TAC estimated by using a pressure monitor 1 week after operation. (B) Representative images of
transthoracic M-mode echocardiographic tracing. Scale bars, 0.2 s and 5 mm, respectively. (C) Echocardiographic parameters of the mice
treated with E6446 4 weeks after TAC (n ¼ 4 in sham groups, n ¼ 5 in TAC groups). Values are mean  SE. *p < 0.05 versus sham-operated
groups. †p < 0.05 versus all other groups. FC ¼ fractional shortening; IVSd ¼ end-diastolic interventricular septal wall thickness; LV ¼ left
ventricular; LVDd ¼ end-diastolic left ventricular internal dimension; LVDs ¼ end-systolic left ventricular internal dimension; LVPWd ¼ end-
diastolic left ventricular posterior wall thickness; other abbreviation as in Figure 1.
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FIGURE 5 Improvement of Cardiac Phenotypes by Treatment With E6446 Initiated Before TAC
The treatment with E6446 was performed every 2 days from 2 days before TAC. The mice were analyzed 4 weeks after the operation (see Figure 10A). (A) Physiological
parameters of the mice treated with E6446 (n ¼ 4 in sham groups, n ¼ 5 in TAC groups). (B) The representative images of WGA-Alexa 555–stained heart sections. Scale
bar, 50 mm. The right graph shows the cross-sectional area of cardiomyocytes. (C) Azan-Mallory–stained heart sections. Left and middle panels show the whole heart
and magnified sections, respectively. Scale bars, 1 mm (left panels) and 100 mm (middle panels). The right graph shows the ratio of the fibrotic area in the heart. n ¼ 3
in sham-operated groups, n ¼ 5 in TAC-operated saline-treated group, n ¼ 4 in TAC-operated E6446-treated group in B and C. Values are mean  SE. †p < 0.05
versus all other groups. BW ¼ body weight; HW ¼ heart weight; other abbreviations as in Figures 1 and 4.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 4 , N O . 3 , 2 0 1 9 Ueda et al.
J U N E 2 0 1 9 : 3 4 8 – 6 3 TLR9 Inhibitor and Heart Failure
355
FIGURE 6 Effects of E6446 on mRNA Expressions
The treatment with E6446 was performed every 2 days from 2 days before TAC. The mice were analyzed 4 weeks after the operation
(see Figure 10A). Data were normalized to the content of Gapdh mRNA. Values are mean  SE (n ¼ 4 in sham groups, n ¼ 5 in TAC groups).
*p < 0.05 versus all other groups. Abbreviations as in Figures 1, 3, and 4.
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immunohistochemical analysis, frozen heart sections
5-mm thick were fixed in buffered paraformaldehyde
and stained with anti-mouse CD45 (R and D Systems),
CD68 (Bio-Rad, Hercules, California), Ly6G/C (BD
Pharmingen, BD Biosciences, San Jose, California),
CD3 (Abcam), and lysosome-associated membraneprotein (LAMP) 2a (Thermo Fisher Scientific) anti-
bodies. To measure the cardiomyocyte cross-sectional
area, the frozen heart sections were stained with
WGA-Alexa 555 (Thermo Fisher Scientific) for 1 h. The
cardiomyocyte cross-sectional area was measured by
tracing the outline of >100 cardiomyocytes in each
section by using ImageJ software. For detection of
FIGURE 7 Attenuation of Inflammatory Responses With Treatment With E6446 Initiated Before TAC
The treatment with E6446 was performed every 2 days from 2 days before TAC. The mice were analyzed 4 weeks after the operation (see Figure 10A). (A) Immu-
nohistochemical analysis of the heart. Scale bar, 100 mm. The right graphs show the quantitative data for numbers of infiltrated inflammatory cells. (B) Deposition of
mitochondrial deoxyribonucleic acid in lysosomes. Double staining of the heart sections with 5-ethynyl-20-deoxyuridine (EdU) (green) and anti–lysosome-associated
membrane protein (LAMP) 2a antibody (red). Low-magnified images are shown in left panels. Scale bar, 10 mm. Higher magnified images of the squared areas are
shown in right panels. Scale bar, 2 mm. Arrows indicate EdU and LAMP2a merged deposits. The left graph shows the number of EdU- and LAMP2a double-positive
deposits. n ¼ 3. Values are mean  SE. *p < 0.05 versus sham-operated groups. †p < 0.05 versus all other groups. Abbreviations as in Figures 1 and 4.
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FIGURE 8 Improvement of Echocardiographic Parameters and Lung Congestion After Treatment With E6446 Initiated After TAC
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Two weeks after TAC, treatment with E6446 was performed every 2 days (see Figure 10B). Values are mean  SE (n ¼ 10). (A) Pressure
gradient across TAC estimated by using a pressure monitor 1 week after operation. (B) Representative images of transthoracic M-mode
echocardiographic tracing. Scale bars, 0.2 s and 5 mm, respectively. (C) Echocardiographic parameters. The parameters were examined for 6
weeks after TAC. Open and closed circles indicate saline-treated control groups and E6446-treated groups, respectively. The data were
analyzed by using 2-way repeated measure analysis of variance followed by Tukey’s post hoc test. *p < 0.05 between the 2 groups at the
corresponding time point. Dotted lines indicate p < 0.05 between the 2 saline-treated control groups at different time points. Solid lines
indicate p < 0.05 between the 2 E6446-treated groups at different time points. (D) Physiological parameters 6 weeks after the operation.
*p < 0.05 versus saline-treated control group. Abbreviations as in Figures 1, 4, and 5.
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TABLE 2 Echocardiographic Parameters of Mice Included in the E6646 Treatment Study
2 Weeks After TAC Operation
Baseline 2 Weeks After TAC
Saline (n ¼ 10) E6446 (n ¼ 10) Saline (n ¼ 10) E6446 (n ¼ 10)
LVDd, mm 2.30  0.03 2.27  0.03 2.81  0.03* 2.86  0.03*
LVDs, mm 0.88  0.02 0.86  0.02 1.54  0.03* 1.55  0.02*
LVFS, % 61.5  0.71 62.3  0.79 45.2  0.77* 45.6  0.43*
IVSd, mm 0.92  0.01 0.92  0.01 1.07  0.01* 1.05  0.01*
LVPWd, mm 0.86  0.02 0.87  0.01 1.04  0.01* 1.03  0.01*
Heart rate, beats/min 692  3.9 695  6.5 689  7.2 672  7.5
LV mass, mg 58.2  1.4 58.9  1.1 103.5  3.1* 101.4  2.1*
Values are mean  SE. Thirty mice were subjected to TAC operation for 2 weeks. Ten mice with fractional
shortening >50% were excluded from the study. The remaining 20 mice were randomized to the saline- and
E6446-treated groups. The parameters of the mice were obtained 2 weeks after the operation by using echo-
cardiography. *p < 0.05 vs. corresponding control at baseline.
Abbreviations as in Table 1.
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359mitochondrial DNA, mice were intraperitoneally
injected with 5 mg of 5-ethynyl-20-deoxyuridine (EdU)
(Invitrogen) 1 day before sacrifice. EdU was detected
by using a Click-iT EdU Alexa Fluor 488 Imaging Kit
(Thermo Fisher Scientific) (7). EdU- and LAMP2a
double-positive deposits were counted in 5 different
areas per section in each mouse.
STATISTICAL ANALYSIS. Results are shown as mean
 SE. GraphPad Prism version 7.04 (GraphPad Soft-
ware, La Jolla, California) was used for statistical
analysis. A Student’s t-test was used for a 2-group
comparison; a 1-way analysis of variance followed
by Tukey’s post hoc test or 2-way repeated measure
analysis of variance followed by Tukey’s post hoc test
were used for multiple comparisons. Significant dif-
ferences were defined as p < 0.05.
RESULTS
EFFECT OF E6446 ON CYTOKINE mRNA PRODUCTION IN
ISOLATED CARDIOMYOCYTES. Isolated cardiomyocytes
were stimulated by a TLR9 ligand (e.g., ODN1668), a
TLR4 ligand (e.g., LPS), or a TLR7 ligand (e.g., loxor-
ibine) in the presence of increasing concentrations of
E6446 (11,12). ODN1668 significantly increased the
expression levels of Il6, IL-1B (Il1b), and Tnfa mRNAs
(Figure 1A). Incubation of cardiomyocytes with E6446
significantly reduced the induction of Il6, Il1b, and
Tnfa mRNAs in response to ODN1668. LPS signifi-
cantly increased the expression levels of Il6, Il1b, and
Tnfa mRNAs, whereas loxoribine significantly
increased the expression levels of Il1b and Tnfa
mRNAs but not Il6 mRNA (Figures 1B and 1C). E6446
had no effect on the induction of the cytokine mRNAs
induced by LPS or loxoribine.
Incubation of cardiomyocytes with CCCP dimin-
ished mitochondrial membrane potential (Figure 2A).
Cardiomyocytes were stained with PicoGreen, a highly
sensitive marker for DNA, and anti-LC3B antibody, a
marker for autophagosomes. CCCP increased the
number of PicoGreen and LC3B double-positive de-
posits, suggesting accumulation of DNA in autopha-
gosomes or autolysosomes (Figure 2B). Incubation of
cardiomyocytes with CCCP increased the levels of Il6
and Il1bmRNAs (Figure 2C). E6446 had no effect on the
number of PicoGreen and LC3B double-positive de-
posits, but it significantly reduced Il6 and Il1b mRNA
expression in CCCP-treated cardiomyocytes.
IN VIVO ADMINISTRATION OF E6446. To examine
the in vivo efficacy of E6446 on inhibition of TLR9
and determine the experimental conditions for its
administration in mice, 1.5 mg/mouse (60 mg/kg) of
E6446 was orally administered to mice 3, 2, or 1 day
before intraperitoneal injection of ODN1668. Twohours after the mice were administered ODN, the
treated mice produced a higher level of IL-6 than
control mice (Figure 3A). When E6446 was adminis-
tered 2 or 1 day before ODN1668 injection, IL-6 levels
were lower than the E6446-nontreated ODN1668-
injected group and showed no significant difference
compared with the control group without ODN1668
injection. When E6446 was administered 3 days
before ODN1668 injection, the level of IL-6 did not
differ from that in the nontreated group. To confirm
the protein data, mRNA levels in the heart were
measured (Figure 3B). The level of Il6 mRNA in
ODN1668-injected mouse hearts was higher than that
in control hearts. When E6446 was administered 2 or
1 day before ODN1668 injection, Il6 mRNA levels were
lower than the E6446-nontreated ODN1668-injected
group. When E6446 was administered 3 days before
ODN1668 injection, the level of Il6 mRNA differed
from the control group but not from other ODN1668-
injected groups. The level of Il1b mRNA in the
E6446-nontreated ODN1668-injected mouse hearts
was higher than that in the control hearts and showed
a significant difference from that treated with E6446 1
and 2 days but not 3 days before ODN1668 injection;
the levels of IL-1B protein were not significantly
different among groups. The level of TNF-a in the
ODN1668-injected mouse group was higher than that
in the nontreated control group and in all the E6446-
treated ODN1668-injected groups. The level of Tnfa
mRNA in E6446-nontreated ODN1668-injected mouse
hearts was higher than that in control hearts but
showed no difference from all other groups. Thus, the
inhibitory effect of E6446 on the induction of cyto-
kines lasted over a period of 2 days, providing a
rationale for every-other-day dosing.
The dose of E6446 necessary to inhibit the induc-
tion of cytokines was next examined. The serum level
FIGURE 9 Schematic Protocol to Determine the Experimental Conditions for
E6446 Administration
-3 days -2 days -1 day 0 hr 2 hrs-0.5 hr
E6446 3 days, ODN1668
E6446 2 days, ODN1668
E6446 1 day, ODN1668
E6446(-), ODN1668
E6446(-), control
A
E6446 1.5 mg/mouse
ODN1668 60 μg/mouse sacrificed
D-galactosamine 20 mg/mouse
n=3 in each group
B -2 days 0 hr 2 hrs-0.5 hr
E6446 15 mg/mouse, ODN1668
E6446 1.5 mg/mouse, ODN1668
E6446 0.15 mg/mouse, ODN1668 
E6446 at the indicated dose
ODN1668 60 μg/mouse sacrificed
D-galactosamine 20 mg/mouse
E6446 0 mg/mouse, ODN1668
E6446 0 mg/mouse, control
n=3 in each group
(A) Schematic protocol to examine the time dependence of cytokine protein and mRNA
expression in the heart after injection with ODN1668 (n ¼ 3 for each group). Mice were
pretreated with E6446 1.5 mg/mouse for 1, 2, or 4 days before injection of 60 mg/mouse
of ODN1668. Two hours after ODN1668 injection, mice were sacrificed for analysis,
following treatment with D-galactosamine. (B) Schematic protocol to examine dose
dependency in the inhibition of cytokine expression after ODN1668 injection with
increasing concentrations of E6446 (n ¼ 3 for each group). Two days after administration
with the indicated dose of E6446, mice received 60 mg/mouse of ODN1668, following
D-galactosamine injection. Two h later, mice were sacrificed for analysis. Abbreviations
as in Figures 1 and 3.
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360of IL-6 and TNF-a protein in mice treated with 1.5 or
15 mg/mouse of E6446 was lower than that in non-
treated mice or in mice treated with 0.15 mg/mouse
of E6446 but did not differ from that in control mice
(Figure 3C). ODN1668 injection increased serum levels
of IL-1B protein. E6446 administration produced no
significant inhibitory effect on the increase of IL-1B
protein. The levels of Il6, Il1b, and Tnfa mRNAs in
hearts treated with 1.5 or 15 mg/mouse were signifi-
cantly lower than those in the hearts of nontreated
mice (Figure 3D). Thus, 1.5 mg/mouse of E6446 was
administered every 2 days in the following
experiments.PREVENTION OF THE DEVELOPMENT OF HEART
FAILURE BY E6446. To investigate the efficacy of
E6446 on the development of heart failure, mice
orally received E6446 or saline 2 days before TAC and
every 2 days for 4 weeks thereafter. There was no
significant difference in pressure gradient across TAC
between the E6446- and saline-treated groups 1 week
after TAC (Figure 4A). Four weeks after TAC, saline-
treated mice exhibited larger end-diastolic LV inter-
nal dimensions and end-systolic LV internal
dimensions and lower fractional shortening than
those in the sham-operated saline-treated group
(Figures 4B and 4C). E6446 treatment significantly
reduced LV chamber size and improved cardiac func-
tion in TAC-operated mice. TAC increased end-
diastolic interventricular septal wall thickness (IVSd)
and end-diastolic LV posterior wall thickness in sa-
line- and E6446-treated mice. However, there were no
significant differences in IVSd and end-diastolic LV
posterior wall thickness between saline- and E6446-
treated mice. LV mass was increased by TAC, and
E6446 treatment attenuated the increase in LV mass
in TAC-operated mice.
There was no significant difference in body weight
between the 4 groups (Figure 5A). TAC-operated sa-
line-treated mice exhibited increases in the heart
weight–to–tibia length ratio and the lung weight–
to–tibia length ratio. E6446 significantly attenuated
cardiac hypertrophy and lung congestion. TAC
increased the cross-sectional area of cardiomyocytes
in saline-treated mice, and the increase was signifi-
cantly attenuated by E6446 treatment (Figure 5B).
Nppa and Nppb mRNAs increased in TAC-operated
saline-treated mice. E6446 attenuated the increases
induced by TAC (Figure 6). TAC-operated saline-
treated mice exhibited cardiac fibrosis, which was
diminished in E6446-treated mice (Figure 5C). The
mRNA levels of Col1a2 and Col3a1 increased in TAC-
operated saline-treated mice. E6446 attenuated the
increase in the mRNAs.
ATTENUATION OF INFLAMMATION IN
PRESSURE-OVERLOADED HEARTS BY E6446. TAC-
operated saline-treated mice showed infiltration of
CD45þ cells, including CD68þ macrophages in the
heart, which was inhibited by treatment with E6446
(Figure 7A). Although increases in the mRNA expres-
sions of Il6 and Tnfa were detected in saline-treated
TAC-operated mice, E6446 attenuated the induction
of the mRNAs (Figure 6).
To label mitochondrial DNA, mice were injected
with EdU 1 day before sacrifice. EdU specifically binds
to mitochondrial DNA during active DNA synthesis
in nondividing cardiomyocytes (7). LAMP2a is a
marker for lysosomes. In TAC-operated saline- and
FIGURE 10 Schematic Protocols to Examine the Effect of E6446 on TAC-Induced
Heart Failure
-Day 2 Day 0 Day 2 Day 4 Day 6 Day 7 Day 8 ......... Week 4
saline group
(n=9)
sham
(n=4)
TAC
(n=5)
E6446 group
(n=9) TAC
(n=5)
sham
(n=4)
saline
blood pressure measurement echo and sacrificed
sham surgeryE6446 TAC surgery
⎧ ⎨ ⎩
administration
every two
days
-Week 2 -Week 1 Day 0 Day 2 Day 4 ......... Week 4
⎧ ⎨ ⎩
administration
every two
days
TAC
(n=30) BP echo E6446 group
(n=10)
saline group
(n=10)
excluded
(n=10)
saline echo and sacrificedE6446 1.5 mg/mouse
A
B
(A) Schematic protocol to examine the effect of treatment with E6446 initiated before
TAC on cardiac phenotypes. E6446 (1.5 mg/mouse) (n ¼ 9) or saline (n ¼ 9) was
administered every 2 days from 2 days before TAC. Blood pressure was measured 7 days
after TAC. Four weeks after TAC, mice were subjected to echocardiographic analysis and
sacrificed. (B) Schematic protocol to examine the effect of treatment with E6446
initiated after TAC on cardiac phenotypes. Thirty mice were subjected to TAC operation
for 2 weeks. Ten mice with fractional shortening >50% were excluded from the study.
The remaining 20 mice were randomized to the saline- and E6446-treated groups and
then administered saline or E6446 (1.5 mg/mouse) every 2 days. Six weeks after TAC,
mice were subjected to echocardiographic analysis and sacrificed. Abbreviations as in
Figures 1 and 4.
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361E6446-treated hearts, EdU and LAMP2a double-
positive deposits were observed (Figure 7B). There
was no significant difference in the number of the
double-positive deposits between TAC-operated sa-
line- and E6446-treated hearts.
SLOWING THE PROGRESSION OF HEART FAILURE
BY E6446. Finally, the effect of E6446 on the pro-
gression of an already established disease was exam-
ined. Mice were subjected to TAC operation (Figure
8A) and divided into 2 groups 2 weeks later. There
were no significant differences in echocardiographic
parameters between the 2 groups, which already
exhibited chamber dilatation and cardiac dysfunction
(Table 2). The mice were then administered E6446 or
saline every 2 days for 4 weeks. LV chamber dilatation
and cardiac dysfunction progressively worsened with
time in both groups (Figures 8B and 8C). End-diastolic
LV internal dimensions, end-systolic LV internal di-
mensions, and LV mass showed no significant differ-
ence between saline- and E6446-treated TAC-
operated mice until 3 weeks after TAC. However, the
parameters were significantly smaller in E6446-
treated mice than those in saline-treated mice 4 and
6 weeks after the operation. Fractional shortening was
significantly higher in E6446-treated mice than that in
saline-treated mice 6 weeks after TAC. There were no
significant differences in IVSd and end-diastolic LV
posterior wall thickness between the 2 groups at any
time point. The heart weight–to–tibia length and lung
weight–to–tibia length ratios were significantly
reduced by E6446 treatment (Figure 8D). Schematic
protocols to examine the effect of treatment of E6446
on cardiac phenotypes are described in Figures 9
and 10.
DISCUSSION
The present study showed that E6446 prevents the
development of pressure overload–induced heart
failure when administered before the cardiac event
and also suppresses the progression of heart failure
when started after cardiac dysfunction manifested.
We have reported that TLR9 is essential in producing
inflammatory cytokines in failing hearts (7). TLRs are
essential in driving the recruitment of inflammatory
cells and production of cytokines during cardiac
remodeling (13). E6446 prevents cellular events acti-
vated by TLR9, exerting broader inhibitory effects on
inflammatory cytokine production, and thus the
treatment of heart failure with the inhibitor has an
advantage over the therapy neutralizing only 1 cyto-
kine. The near-complete rescue of TAC-induced LV
dilatation and dysfunction by E6446 pretreatment
suggests that the TLR9-signaling pathway is thedominant pathway for inducing adverse ventricular
remodeling, with a limited role for other pathways
such as nucleotide-binding domain leucine-rich
repeat containing protein 3 (NLRP3) and cyclic
GMP-AMP synthase (cGAS)-stimulator of interferon
genes (STING) activation by mitochondrial DNA
released in the cytosol in the setting of mitophagy
dysfunction (14).
In human peripheral blood mononuclear cells or
mouse spleen cells, E6446 diminished IL-6 produc-
tion in response to CpG ODN (8). A 100-fold higher
concentration of E6446 inhibited cytokine produc-
tion in response to the imidazoquinoline compound
R848, which is a TLR7/8 agonist (15). When C57BL/6
mice were orally treated with E6446, E6446
completely inhibited CpG ODN–induced IL-6 pro-
duction in sera but not R848- and LPS-mediated
cytokine production (8). Consistent with these re-
sults, our findings indicate that E6446 specifically
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362inhibited the expression of inflammatory cytokines
through a TLR9-dependent pathway but not TLR4-
or TLR7-dependent pathways in adult car-
diomyocytes. Thus, E6446 has high specificity to
TLR9. In mouse bone marrow–derived dendritic
cells, E6446 potently inhibited IL-6 production
induced by CpG ODN but not by TLR3 ligands (9).
However, E6446 was a potent inhibitor of IL-6 in-
duction by single-stranded RNA, a TLR7/8 agonist,
but a relatively poor inhibitor of IL-6 induction by
R848, suggesting that the ability of E6446 to sup-
press TLR7/8 might be ligand dependent. Based on
our data showing the importance of TLR9 signaling
in the development of inflammation and heart fail-
ure and its specificity to TLR9 in cardiomyocytes,
the cardioprotective action of E6446 is TLR9 medi-
ated. However, we cannot exclude the possibility
that TLR7/8 is involved in the effect of E6446 on
the development of heart failure.
E6446 inhibits in vitro DNATLR9 interaction via an
association with DNA but not with TLR9 (9). Further-
more, E6446 accumulates in the intracellular acidic
compartment. Mitochondrial DNA is accumulated in
autolysosome and coexists with TLR9 in failing hearts
(7). DNase II activity was up-regulated in hypertro-
phied hearts but not in failing hearts. The incomplete
digestion of mitochondrial DNA would be due to the
loss of up-regulation of DNase II activity. Mitophagy
impairment occurs in the TAC-induced mouse heart
failure model (16). Thus, it is also possible that
impairment of mitophagy or lysosomal permeabiliza-
tion or lysosomal dysfunction might result in the
accumulation of mitochondrial DNA in autolysosome.
Our data in this study showed that there was no sig-
nificant difference in the number of EdU and LAMP2a
double-positive deposits between TAC-operated sa-
line- and E6446-treated hearts. This outcome suggests
that E6446 has no effect on mitochondrial DNA accu-
mulation in autolysosomes. Thus, we can assume that
the E6446 administered accumulates in lysosomes in
the cardiomyocytes and interacts with mitochondrial
DNA. When E6446 was orally administered to mice
before TAC, E6446 inhibited TLR9 signaling by inter-
fering with the mitochondrial DNATLR9 interaction
and subsequent development of inflammation and
heart failure.
We showed that Tlr9–/– mice are more resistant to
pressure overload than control mice, and inhibitory
ODN to TLR9 (ODN2088) improved survival in TAC-
operated wild-type mice when administered before
TAC (7). However, administration of a drug before
cardiac events is not clinically relevant. The results
indicate that E6446 can slow the development of
heart failure even after cardiac dysfunctionmanifested. Thus, E6446 or other immunomodula-
tory therapy can be used to prevent or delay pressure
overload–induced heart failure.
STUDY LIMITATIONS. This study shows the thera-
peutic effects of a TLR9 inhibitor, E6446, on mouse
pressure-overload heart failure model. Obviously,
further studies are necessary to translate the findings
into human heart failure therapy. TAC-induced mouse
model does not fully represent the complex features of
clinical heart failure. To establish the clinical feasi-
bility of E6446 treatment for heart failure, the effects
of E6446 on different heart failure models have to be
examined, such as myocardial infarction. In addition,
we used young healthy mice in this study. However, in
most patients, and particularly in elderly patients,
heart failure is accompanied by a range of comorbid-
ities, such as hypertension, diabetes mellitus, renal
dysfunction and hyperlipidemia. Such factors may
influence on the cardioprotective effect of E6446 in
heart failure. Thus, further investigation using various
disease models is required to clarify the clinical target
of E6446 treatment. Furthermore, it will be important
to validate the findings in large animal models and
ultimately in human patients. It remains unclear
whether mitochondrial DNA is accumulated in auto-
lysosomes and mitochondrial DNA-TLR9 axis is
involved in the genesis of inflammation in human
failing hearts.
CONCLUSIONS
Heart failure is the result of various cardiac diseases
such as myocardial infarction, high blood pressure,
cardiomyopathy, valvular diseases, arrhythmia, and
congenital heart diseases. Elevated levels of inflam-
matory mediators have been identified in patients
with heart failure, including heart failure with
reduced and preserved ejection fraction, as well as
short-term decompensated heart failure (1). Thus,
investigation of the involvement of the TLR9-
signaling pathway in other mouse or larger animal
heart failure models and various types of human
heart failure is warranted. We ultimately will be able
to identify subsets of patients with heart failure who
will benefit from inhibition of TLR9 signaling.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Heart
failure is a major health threat in the developed countries
with high morbidity and mortality. Novel and effective
therapeutic agents against heart failure need to be
developed. Inflammation and proinflammatory cytokines
play an important role in the pathogenesis of heart fail-
ure. Inflammatory mediators can be therapeutic targets in
heart failure.
TRANSLATIONAL OUTLOOK: A TLR9 inhibitor,
E6446, exerted a beneficial effect on attenuating the
development or progression of heart failure in a pressure
overload–induced mouse model. E6446 treatment has an
advantage over targeted anticytokine approaches using
biological response modifiers, because it modulates a
broad spectrum of inflammatory mediators. Thus, it may
be a new promising therapeutic agent for human heart
failure.
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